REQUEST A DEMO
Total
USD $0.00
Search more companies

Pymepharco (Vietnam)

Main Activities: Pharmaceutical and Medicine Manufacturing | Drugs and Druggists' Sundries Merchant Wholesalers
Full name: Pymepharco Profile Updated: February 21, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2022 Available in: English Download a sample report

The subject engages in manufacturing, trading, importing and exporting pharmaceutical products, medical equipment, materials and related chemicals. Strong brands are Tatanol, Coldflu Forte, Menison, Liverton, Vivace… As investigated, the subject was officially delisted on 06 Dec 2021 because it is not eligible as a public company according to the announcement of the State Securities Commission based on Point a, Clause 1, Article 120 of Decree 155/2020/ND-CP dated on 31 Dec 2020.Stada Arzneimittel AG through Stada Service Holding B.V. acquired the subject, from 49% in 2017 to 99.73% in 2021 to establish a basis for the Stada Group's expansion in Vietnam, one of the most important growth markets in Asia. Stada Arzneimittel AG has 100% interest in the subject's parent company.Besides the subject, Stada Group engaged in operation of other companies in Vietnam such as Stellapharm J.V. Co., Ltd. Due to the 50-50 joint venture status, Stellapharm J.V. Co., Ltd (former name: Stada - VN Joint Venture Co., Ltd) started to suffer certain restrictions in growth strategy and the difference in strategic development of shareholders. Thus, Stada Group divested all capital contributions in Stellapharm J.V. Co., Ltd and established a new company - Stada Vietnam Limited Liability Company in 2020. The subject and this company have the same address and are members of Stada Group. These facts indicate that Stada Group has pursued the expansion strategy through M&A and joint venture deals in the Vietnamese market.Most prominently, the authorities in EU confirmed that Stada Group's plant in Tuy Hoa City, Vietnam, meets European GMP (Good Manufacturing Practice) standards. This means that in the future the Group will also be able to produce in Vietnam to serve EU markets. With initiatives such as photovoltaic cells in Vietnam, this helps to save around 2,500 tons of CO2 in 2022. Being as one of 20 production sites of the Group with constant innovatations, Stada Group aspires to advance its contribution to sustainable pharmaceutical supply, minimize supply bottlenecks and ensure security of supply in Vietnam and other markets in the world.

Headquarters
No. 166 - 170, Nguyen Hue Street, Ward 7
Tuy Hoa; South Central Coastal Vietnam; Postal Code: 56000

Contact Details: Purchase the Pymepharco report to view the information.

Website: http://www.pymepharco.com

Basic Information
Total Employees:
Purchase the Pymepharco report to view the information.
Outstanding Shares:
Purchase the Pymepharco report to view the information.
Registered Capital:
Purchase the Pymepharco report to view the information.
Financial Auditors:
Purchase the Pymepharco report to view the information.
Incorporation Date:
May 03, 2006
Key Executives
Purchase this report to view the information.
General Director
Ownership Details
Purchase this report to view the information.
89.733%
Purchase this report to view the information.
0.018%
Subsidiaries
Phu Yen Pharmaceutical Import Export Joint Stock Company
Quang Tri Pharmaceutical Material Joint Stock Company
Stada Vietnam Limited Liability Company
Company Performance
Financial values in the chart are available after Pymepharco report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency VND. Absolute financial data is included in the purchased report.
Net sales revenue
-10.06%
Total operating revenue
-10.06%
Operating profit (EBIT)
-69.82%
EBITDA
-58.92%
Net Profit (Loss) for the Period
-76.72%
Total assets
-2.57%
Total equity
-0.21%
Operating Profit Margin (ROS)
-11.8%
Net Profit Margin
-10.06%
Return on Equity (ROE)
-10.68%
Debt to Equity Ratio
-1.5%
Quick Ratio
-0.25%
Cash Ratio
0.1%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?